Supernus Pharmaceuticals Files 8-K on Ethics Code and Exhibits
Ticker: SUPN · Form: 8-K · Filed: 2024-12-20T00:00:00.000Z
Sentiment: neutral
Topics: ethics, exhibits, filing
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K for ethics code updates and financial exhibits.
AI Summary
On December 19, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns amendments to the company's Code of Ethics and the inclusion of financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates updates to Supernus Pharmaceuticals' internal governance and compliance procedures, as well as the submission of required financial documentation.
Risk Assessment
Risk Level: low — The filing is procedural, detailing updates to the code of ethics and submission of exhibits, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific amendments were made to Supernus Pharmaceuticals' Code of Ethics?
The provided excerpt of the 8-K filing states that the report concerns 'Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics,' but does not detail the specific nature of these amendments.
What financial statements and exhibits are included in this 8-K filing?
The filing indicates the inclusion of 'Financial Statements and Exhibits,' but the specific contents are not detailed in the provided text.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 19, 2024.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive office address is 9715 Key West Ave, Rockville, MD 20850.
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-20 16:10:58
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20241219.htm (8-K) — 28KB
- ex141-codeofethicsandbusin.htm (EX-14.1) — 105KB
- image_0.jpg (GRAPHIC) — 7KB
- image_1.jpg (GRAPHIC) — 0KB
- image_2.jpg (GRAPHIC) — 73KB
- image_3.jpg (GRAPHIC) — 56KB
- 0001356576-24-000069.txt ( ) — 464KB
- supn-20241219.xsd (EX-101.SCH) — 2KB
- supn-20241219_lab.xml (EX-101.LAB) — 21KB
- supn-20241219_pre.xml (EX-101.PRE) — 12KB
- supn-20241219_htm.xml (XML) — 3KB
05
Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics. On December 19, 2024, the Board of Directors of the Company approved and adopted an updated Code of Ethics and Business Conduct (the "Code"). The Code applies to all of the Company's employees, directors, and contract workers. Among other things, the updated Code clarifies the reporting channels available to employees, directors and contract workers and potential consequences for violations of the Code, and also provide additional guidance on avoiding conflicts of interest and complying with applicable laws and regulations. The foregoing summary of the Code is qualified in its entirety by reference to the full text of the Code, a copy of which is attached as Exhibit 14.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.05. Amending the Code did not result in a waiver or implicit waiver (as defined in Instruction 2 to Item 5.05) of the previous Code. The Code will be posted as soon as practicable in the Investor Relations section of the Company's website, https://ir.supernus.com.
01
Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 14.1 — Code of Ethics and Business Conduct 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: December 20, 2024 By: /s/ Timothy Dec Timothy Dec Senior Vice-President and Chief Financial Officer 3